Modifying the Poor Prognosis Associated with 18F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

TO THE EDITOR: Applying conventional diagnostic imaging paradigms, a negative 18F-FDG PET/CT study in a patient with biopsy-proven metastatic neuroendocrine tumor (NET) would be considered false-negative. With molecular imaging, however, we have emerged from using imaging merely to detect and